T1156 Cell-Surface Galectin-3 Confers Resistance to Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL) by Impeding Trafficking of DR4 Death Receptors in Colon Cancer Cells

2010 ◽  
Vol 138 (5) ◽  
pp. S-500
Author(s):  
Nachman Mazurek ◽  
James C. Byrd ◽  
Yun Jie Sun ◽  
Robert S. Bresalier
Keyword(s):  
Colon Cancer ◽  
Tumor Necrosis Factor ◽  
Cell Surface ◽  
Cancer Cells ◽  
Tumor Necrosis ◽  
Death Receptors ◽  
Colon Cancer Cells ◽  
Galectin 3 ◽  
Necrosis Factor

Human urokinase receptor expression is inhibited by amiloride and induced by tumor necrosis factor and phorbol ester in colon cancer cells

FEBS Letters ◽  
1994 ◽  
Vol 353 (2) ◽  
pp. 138-142 ◽  
Author(s):  
Yao Wang ◽  
Caroline J. Jones ◽  
Jinjun Dang ◽  
Xiaoming Liang ◽  
Jane E. Olsen ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Tumor Necrosis Factor ◽  
Cancer Cells ◽  
Phorbol Ester ◽  
Tumor Necrosis ◽  
Urokinase Receptor ◽  
Receptor Expression ◽  
Colon Cancer Cells ◽  
Necrosis Factor

scholarly journals Cytokine Induction of Tumor Necrosis Factor Receptor 2 Is Mediated by STAT3 in Colon Cancer Cells

2011 ◽  
Vol 9 (12) ◽  
pp. 1718-1731 ◽  
Author(s):  
Kathryn E. Hamilton ◽  
James G. Simmons ◽  
Shengli Ding ◽  
Laurianne Van Landeghem ◽  
P. Kay Lund
Keyword(s):  
Colon Cancer ◽  
Tumor Necrosis Factor ◽  
Cancer Cells ◽  
Tumor Necrosis ◽  
Tumor Necrosis Factor Receptor ◽  
Colon Cancer Cells ◽  
Cytokine Induction ◽  
Necrosis Factor

Kaempferol Improves TRAIL-Mediated Apoptosis in Leukemia MOLT-4 Cells by the Inhibition of Anti-apoptotic Proteins and Promotion of Death Receptors Expression

2019 ◽  
Vol 19 (15) ◽  
pp. 1835-1845
Author(s):  
Ali Hassanzadeh ◽  
Adel Naimi ◽  
Majid F. Hagh ◽  
Raedeh Saraei ◽  
Faroogh Marofi ◽  
...  
Keyword(s):  
Tumor Necrosis Factor ◽  
Cancer Cells ◽  
Tumor Necrosis ◽  
Lymphoblastic Leukemia ◽  
Annexin V ◽  
Death Receptors ◽  
Target Cells ◽  
Wide Range ◽  
Apoptotic Proteins ◽  
Necrosis Factor

Introduction: Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL or Apo2L) is a member of the tumor necrosis factor (TNF) superfamily, which stimulates apoptosis in a wide range of cancer cells via binding to death receptors 4 and 5 (DR4/5). Nevertheless, TRAIL has noticeable anti-cancer abilities; some cancer cells acquire resistance to TRAIL, and consequently its potential for inducing apoptosis in target cells is strongly diminished. Acute lymphoblastic leukemia MOLT-4 cell line is one of the most resistant cells to TRAIL that developed resistance to TRAIL via different pathways. We used TRAIL plus kaempferol to eliminate resistance of the MOLT-4 cells to TRAIL. Material and Methods: First, IC50 for kaempferol (95 µM) was determined by using the MTT assay. Second, the viability of the MOLT-4 cells was assayed by FACS after Annexin V/PI staining, following treatment with TRAIL (50 and 100 nM) and kaempferol (95 µM) alone and together. Finally, the expression levels of the candidate genes involved in resistance to TRAIL were assayed by real-time PCR technique. Results: Kaempferol plus TRAIL induced apoptosis robustly in MOLT-4 cells at 12, 24 and 48 hours after treatment. Additionally, we found that kaempferol could inhibit expression of the c-FLIP, X-IAP, cIAP1/2, FGF-8 and VEGF-beta, and conversely augment expression of the DR4/5 in MOLT-4 cells. Conclusion: We suggest that co-treatment of MOLT-4 cells with TRAIL plus kaempferol is a practical and attractive approach to eliminate cancers’ resistance to TRAIL via inhibition of the intracellular anti-apoptotic proteins, upregulation of DR4/5 and also by suppression of the VEGF-beta (VEGFB) and FGF-8 expressions.

Sign in / Sign up

Export Citation Format

Share Document